BMS-986470 for Sickle Cell Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment, BMS-986470, to evaluate its safety and effectiveness for people with sickle cell disease and healthy volunteers. Sickle cell disease can cause pain and other serious health issues. The trial seeks healthy individuals and those with sickle cell disease who have experienced multiple painful episodes, known as vaso-occlusive crises, in the past year. Participants will help researchers understand the treatment's effects and how the body processes it. As a Phase 1 trial, this research focuses on understanding the treatment's function in people, offering participants the opportunity to be among the first to receive it.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are receiving regular blood transfusions, you may not be eligible to participate.
Is there any evidence suggesting that BMS-986470 is likely to be safe for humans?
Research shows that BMS-986470 is being tested for safety in treating sickle cell disease. In earlier studies, most participants tolerated the treatment well, with no reports of serious side effects. Some experienced mild issues like headaches and nausea, common with many treatments, which did not halt the study.
The treatment remains in the early testing phase, so researchers continue to assess its safety. While initial results are encouraging, more research is needed to fully understand its safety profile. The continuation of the study suggests confidence in its potential safety for patients.12345Why do researchers think this study treatment might be promising for sickle cell disease?
Most treatments for sickle cell disease, like hydroxyurea and blood transfusions, aim to manage symptoms and prevent complications. But BMS-986470 is unique because it targets sickle cell disease at the root by aiming to modify the underlying causes of the disease rather than just treating symptoms. Researchers are excited about this treatment because it could potentially reduce the frequency of painful episodes and improve overall quality of life for patients. This new approach offers hope for a more effective and long-lasting impact compared to existing therapies.
What evidence suggests that BMS-986470 might be an effective treatment for sickle cell disease?
Research shows that BMS-986470, which participants in this trial may receive, is designed to help people with sickle cell disease by increasing levels of fetal hemoglobin (HbF). Fetal hemoglobin can prevent red blood cells from becoming sickle-shaped, a major issue in this disease. While researchers are still learning about its effectiveness in humans, this treatment modifies certain proteins to boost HbF production. Early results from other studies suggest it might be beneficial, but more research is needed to confirm its efficacy for sickle cell disease.12567
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for healthy individuals and those with sickle cell disease. Participants must meet specific health criteria to join, but the exact inclusion and exclusion details are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986470 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986470
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania